Galapagos NV
Belgian pharmaceutical research company / From Wikipedia, the free encyclopedia
Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
Quick Facts Formerly, Company type ...
Formerly | Galapagos Genomics NV |
---|---|
Company type | Naamloze vennootschap |
Euronext Amsterdam: GLPG BEL 20 component | |
ISIN | BE0003818359 |
Industry | Pharmaceutical |
Founded | 1999 |
Headquarters | Mechelen, Belgium |
Key people | Paul Stoffels (CEO) Raj Parekh (Chairman) |
Products | Filgotinib; GLPG1205; GLPG0778 |
Revenue | €288.836 million (2018)[1] |
€-29.259 million (2018)[1] | |
Total assets | €1,439.496 million (2018)[1] |
Total equity | €1,214.249 million (2018)[1] |
Number of employees | 725 (2018)[1] |
Website | www |
Close
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.[2]